Crinetics Pharmaceuticals's total assets for Q3 2024 were $937.37M, an increase of 0.20% from the previous quarter. CRNX total liabilities were $104.39M for the fiscal quarter, a -0.36% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.